Farris, Samantha G.
Legasse, Aubrey J.
Uebelacker, Lisa A.
Brown, Richard A.
Price, Lawrence H.
Abrantes, Ana M.
Funding for this research was provided by:
National Institute on Drug Abuse (R01-CA173551)
National Heart, Lung, and Blood Institute (T32-HL076134-11)
Article History
First Online: 27 July 2018
Compliance with Ethical Standards
:
: Dr. Brown has equity ownership in Health Behavior Solutions, Inc., which is developing products for tobacco cessation although not products directly related to this publication. The terms of this arrangement have been reviewed and approved by the University of Texas at Austin in accordance with its policy on objectivity in research. Dr. Price receives travel funds from Springer and is a consultant to Wiley, Springer, University of Texas at Austin, and the Cleveland Clinic. Dr. Uebelacker’s spouse is employed by AbbVie Pharmaceuticals. Drs. Farris and Abrantes, and Ms. Legasse has no disclosures to report.
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.